

Remarks/Arguments

Applicants have amended the specification to provide the priority claim. The claims have been amended to remove multiple dependencies, correct typographical errors and to otherwise place the claims in an appropriate U.S. format. No new matter has been added by these amendments.

The above amendments have been made without prejudice to Applicants right to prosecute any cancelled subject matter in a timely filed continuation application.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 101064-1P US.

Respectfully submitted,



Name: Carol A. Loeschorn
Dated: 14 February 2006
Reg. No.: 35,590
Phone No.: 781-839-4002

Global Intellectual Property, Patents
AstraZeneca R&D Boston
35, Gatehouse Drive
Waltham, MA 02451